直肠癌新辅助放化疗前后LGR5基因表达的变化及其与疗效的关系

doi:10.3969/j.issn.1004-616x.2017.01.012

Abstract

Abstract:

OBJECTIVE: To investigate changes in expression of the tumor stem cell marker LGR5 gene before and after neoadjuvant chemoradiotherapy and its predictive effect on neoadjuvant chemoradiation. METHODS: Ninety-four rectal cancer patients with preoperative chemoradiotherapy were enrolled in the Affiliated Tumor Hospital of Xinjiang Medical University between January 2014 and February 2016. Quantitative real-time PCR(qRT-PCR) method was used to determine the expression of LGR5 mRNA before and after neoadjuvant chemoradiotherapy. Overall survival(OS) rates were estimated by the Kaplan-Meier method and compared using the Log-rank test for univariate analysis. Cox regression analysis was performed to provide multivariate analysis. RESULTS: Tumor pathological regression reaction of rectal cancer after neoadjuvant chemoradiothepy was good. The efficiency was at 87.2%,and 18.1% patients achieved pathological complete response rate (pCR) after neoadjuvant chemoradiothepy. The expression level of LGR5 mRNA in rectal carcinoma tissues after chemoradiothepy (8.847±6.664) was significantly less than that before chemoradiothepy (14.396±9.924;P < 0.05). The expression level of LGR5 mRNA after chemoradiothepy was up-regulated in 27 patients and down-regulated in 67 patients. Among them,the down-regulated group had significantly better tumor regression degree and 1,2 year-survival rates than that of the up-regulated group. Univariate analysis showed that several factors such as the CA19-9 levels before chemoradiothepy, clinical stage,grade of TRG and expression changes of LGR5 mRNA were significant prognostic factor for OS. CA19-9 levels before chemoradiothepy and expression changes of LGR5 mRNA showed significant differences in multivariate analysis. CONCLUSION: Neoadjuvant chemoradiotherapy caused changes in the expression of LGR5 mRNA. Our study shows that LGR5 mRNA expression changes before and after neoadjuvant chemoradiation and levels before chemoradiothepy had the prognostic potential on the effect of neoadjuvant chemoradiation for locally advanced rectal cancer.

Key words: rectal cancer, neoadjuvant chemoradiotherapy, LGR5 mRNA, tumor regression grade, effect

CLC Number:

730.5

AYIGULI·Hare, LU Yanrong, YISIKANDA·Abulimiti, ZHANG Jinrong. Expression of the LGR5 gene in rectal cancer in response to neoadjuvant chemoradiotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 60-64,69.

References

[1] JEMAL A,SIEGEL R,WARD E,et al. Cancer statistics[J]. CA Cancer J Clin,2008,58(2):71-96.

[2] CHEN Q,LIU Z C,CHENG L P,et al. An analysis of incidence and mortality of colorectal cancer in China[J]. China Cancer,2012,21(3):179-182.

[3] VAN GIJN W,MARIJNEN C A M,NAGTEGAAL I D,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer:12-year follow-up of the multicentre,randomised controlled TME trial[J]. Lancet Oncol, 2011,12(6):575-582.

[4] SAUER R,LIERSCH T,MERKEL S,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after ramedian follow-up of 11 years[J].J Clin Oncol,2012,30(16):1926-1933.

[5] DE CAMPOS-LOBATO L F,STOCEHI L,DA LUZ MOREIRA A,et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence[J]. Ann Surg Oncol,2011,18(6):1590-1598.

[6] MASS M,NELEMANS P J,VALENTINI V,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data[J]. Lancet Oncol,2010,11(9):835-844.

[7] MERLOS-SUAREZ A,BARRIGA FM,JUNG P,et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse[J]. Cell Stem Cell,2011, 8(5):511-524.

[8] WALKER F,ZHANG HH,ODORIZZI A,et al. LGR5 is a negative regulator of tumourigenicity,antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines[J]. PLoS One,2011,6(7):e22733.

[9] 孙艳,盛春华,文大成,等. 人结直肠癌干细胞标志物富含亮氨酸重复单位的G蛋白偶联受体5基因的表达及意义[J]. 中华消化杂志,2013,33(3):187-190.

[10] REYA T,MORRISON SJ,CIARKE MF,et al. Stem cells, cancer,and cancer stem cells[J]. Nature,2001, 414(6859):105-111.

[11] VISVADER J E,LINDEMAN G J. Cancer stem cells in solid tumours:accumulating evidence and unresolved questions[J]. Nat Rev Cancer,2008,8(10) 755-768.

[12] SIMON E,PETKE D,BOGER C,et al. The spatial distribution of LGR5⁺ cells correlates with gastric cancer progression[J]. PLoS One,2012,7(4):e35486.

[13] WANG D,ZHOU J,FAN C,et al. Knockdown of LGR5 suppresses the proliferation of glioma cells in vitro and in vivo[J]. Oncol Rep,2014,31(1):41-49.

[14] SCANNELL C,PEDERSEN E,MOSHER J,et al. LGR5 is expressed by Ewing sarcoma and potentiates Wnt/β-catenin signaling[J]. Front Oncol,2013,doi:10.3389/fonc.2013. 00081.

[15] WU X S,XI H Q,CHEN L. LGR5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival[J]. World J Surg Oncol,2012,10(1):244.

[16] NAKATA S,CAMPOS B,BAGERITZ J,et al. LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells[J]. Brain Pathol, 2013,23(1):60-72.

[17] LIU Z,DAI W,JIANG L,et al. Over-expression of LGR5 correlates with poor survival of colon cancer in mice as well as in patients[J]. Neoplasma,2014,61(2):177-185.

[18] SAIGUSA S,INOUE Y,TANAKA K,et al. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy[J]. J Cancer Res Clin Oncol,2013,139(1):131-138.

[19] VON RAHDEN BH,KIRCHER S,LAZARIOTOU M,et al. LgR5 expression and cancer stem cell hypothesis:clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus[J]. J Exp Clin Cancer Res,2011,30(1):23.

[20] 彭亮,梁纯,梁燕,等. 结直肠癌Lgr5表达对患者预后的影响[J]. 现代消化及介入诊疗,2010,15(5):284-287.

[21] WALKER F,ZHANG H H,ODORIZZI A,et al. LGR5 is a negative regulator of tumourigenicity,antagonizes Wm signalling and regulates cell adhesion in colorectal cancer cell lines[J]. PLoS One,2011,6(7):e22733.

[22] ZISKIN J L,DUNLAP D,YAYLAOGLU M,et al. In situ validation of an intestinal stem cell signature in colorectal cancer[J]. Gut,2013,62(7):1012-1023.

[23] 孙艳武,池畔,徐本华,等. 直肠癌新辅助放化疗后病理完全缓解预测因素分析[J]. 中华胃肠外科杂志,2014,17(6):556-560.

[24] SAIGUSA S,INOUE Y,TANAKA K,et al. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy[J]. Cancer Res Clin Oncol,2013,139(1):131-138.

[25] HSU H C,LIU Y S,TSENG K C,et al.Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer[J]. Int J Colorectal Dis,2013,28(11):1535-1546.

[26] KOBAYASHI S,YAMADA-OKABE H,SUZUKI M,et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconsti-tution[J]. Stem Cells,2012,30(12):2631-2644.

[27] 任俊丽,樊卫平,韩存芝,等. 局部晚期直肠癌新辅助治疗中CEA、CA199的变化及临床意义[J]. 中国当代医药,2015, 22(20):50-56.

[28] 韩潞,江勇,谭卫林. CEA和CA19-9在结直肠癌组织中的表达及临床意义[J]. 实用癌症杂志,2015,30(1):25-27.

Expression of the LGR5 gene in rectal cancer in response to neoadjuvant chemoradiotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	AI Duo, XU Anqi, KONG Deqin, LIU Ying, YU Weihua, WANG Zhao, PENG Jie, LIU Rui, ZHANG Xiaodi, HAI Chunxu, LI Wenli, WANG Xin, LIU Jiangzheng. Protective effects of catalytic antioxidant AEOL-10150 against nitrogen mustard-induced acute liver injury in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 40-46,61.
[2]	ZHU Xinping, JIA Di, LIN Shaohui, LIU Chen, LI Jingyi, ZHAO Weiming. Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 47-52,66.
[3]	LIU Ning, LIANG Lanlan, LI Shufang, SHEN Xiangchun, LIANG Bing. Anti-tumor effects of oxymatrine on mouse sarcoma and live cancers in vivo and in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 426-429,434.
[4]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[5]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[6]	LI Bo, LI Gairui, ZHAO Wei, PENG Xiaolin, ZHAO Dan, PENG Ji. Evaluation of sample preservation solution for fecal DNA detection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 312-316.
[7]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[8]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[9]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.
[10]	ZHU Yiqing, ZHANG Tongtong, ZHENG Junwen, HAO Jiajie, CAI Yan, WANG Mingrong, LIANG Jianwei, ZHANG Yu. Expression status of p-mTOR and its prognostic implication in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 161-165.
[11]	LI Dan, LIU Baoying, YU Mingming, ZHUANG Hailin, JIE Jinhua, WU Hanmei. NFKBIA polymorphism, eating habits and susceptibility to gastric cancer: a case-control study [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 198-202.
[12]	MA Xiaobiao, ZHANG Qi, PAN Dingguo. Association between rs4143815 polymorphism in the B7-H1 gene and risk of colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 440-443,448.
[13]	ZHANG Zhiping, SHAN Baoen, SONG Jingjing, WANG Hao, LIU Yingzi, CHEN Wei, GAO Liping, LI Qiaoxia. Tumorigenic effect of interleukin?17 overexpressing gastric cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 295-299.
[14]	WEI Fenfen, WANG Wenjuan, ZHANG Bo. Protective effects of lycium barbarum polysaccharide on kidney in alcohol-induced liver injury in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 148-152.
[15]	MA Ming, BAI Hanyu, LI Xiaoya, WANG Yanhai, ZHAO Riyang, DAI Suli, WU Yipeng, ZHANG Cong, ZHAO Lianmei, SHAN Baoen. Toxicological effect of p-hydroxylcinnamaldehyde extract from the Cochinchina momordica seeds on mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 452-456,462.